Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups
First-in-human single ascending dose trial advances to high dose cohort following positive Data Monitoring Committee review of mid dose safety data Company to expand FX201 low dose and mid dose cohorts to include up to 20 additional patients in each treatment group Flexion plans to present interim
View HTML
Toggle Summary National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA®
- Sheryl Swoopes, WNBA Legend, Basketball Hall of Famer and ZILRETTA Patient, Tips Off Educational Campaign About ZILRETTA and Osteoarthritis Knee Pain CHICAGO and BURLINGTON, Mass. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- The National Basketball Retired Players Association (NBRPA) and Flexion
View HTML
Toggle Summary Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results
Fourth-quarter 2020  ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales estimated to be approximately $26 .3 million Full-year 2020 net sales estimated to be approximately $85 .5 million Company names Adam Muzikant , Ph.D., Chief Business Officer BURLINGTON, Mass.
View HTML
Toggle Summary Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference
BURLINGTON, Mass. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the ICR | Westwicke Investment Conference . The virtual fireside
View HTML
Toggle Summary Flexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference
BURLINGTON, Mass. , Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of 22,798 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of
View HTML
Toggle Summary Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
BURLINGTON, Mass. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 29 th Annual Credit Suisse Virtual Healthcare Conference . The
View HTML
Toggle Summary Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights
Company   reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23 .7 million in third quarter 2020 BURLINGTON, Mass. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business
View HTML
Toggle Summary Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020
BURLINGTON, Mass. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 4, 2020 . The company hosted a conference call on October
View HTML